







an Open Access Journal by MDPI

# **Genomic Landscape of Myelodysplastic Syndromes**

Guest Editor:

### **Prof. Dr. Nicolas Bonadies**

Hemato-Oncology, Hirslanden Bern, Bern, Switzerland

Deadline for manuscript submissions:

31 December 2024

## Message from the Guest Editor

Dear Colleagues,

The genomic landscape of MDS is complex and heterogeneous, involving a multitude of genetic and epigenetic alterations that drive disease pathogenesis and progression. Understanding these molecular mechanisms is essential for improving risk stratification, developing targeted therapies, and ultimately improving outcomes for patients with MDS.

We encourage researchers to submit articles in this Special Issue dedicated to the diagnostic, prognostic, predictive implications as well as minimial-residual diesease monitoring of genetic and epigenetic alterations in myelodysplastic syndromes. These may include following aspects:

Cytogenetic Abnormalities
Somatic Mutations
Clonal Evolution
Epigenetic Alterations
Clonal Hematopoiesis of Indeterminate Potential
Therapeutic Implications

We look forward to receiving your contributions to further elucidate the genomic landscape of MDS and ultimately offer the potential for better outcomes for patients with this complex disorder.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**